Drugs / Apimostinel
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05597241 | Oct 2022 → Apr 2023 | major depressive disorder | Syndeio Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02366364 | Feb → Apr 2015 | major depressive disorder | Naurex, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01856556 | May 2013 → Nov 2014 | — | Naurex, Inc | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT06400121 | Oct 2024 → Mar 2029 expected | depressive disorder | Rebecca Price | Recruiting | No outcome recorded |
| Phase 2 | NCT02067793 | Mar 2014 → Feb 2015 | major depressive disorder | Naurex, Inc | Completed | Met primary |
| Phase 2 | NCT02603458 | ? → Aug 2020 | schizophrenia | NYU Langone Health | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-15 | Syndeio Biosciences, Inc | Results Gate Neurosciences to share new data and research on its synaptic function molecules with multiple posters at 2024 ASCP meeting syndeio.bio ↗
Single dose of apimostinel acutely enhanced LTP with metaplasticity lasting 7 days, and produced robust antidepressant-like effects |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-03 | Syndeio Biosciences, Inc | Gate Neurosciences and University of Pittsburgh Collaborate to Initiate Phase 2 Trial Combining Apimostinel with Digital Therapeutic for Depression syndeio.bio ↗ |
| 2024-05-15 | Syndeio Biosciences, Inc | Gate Neurosciences to share new data and research on its synaptic function molecules with multiple posters at 2024 ASCP meeting syndeio.bio ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apimostinel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06400121 ↗ |
| Known as | NRX-1074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02067793 ↗ |
| Action | Activate | “functional partial agonist” NCT02067793 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3989872 ↗ |
| Route | Intravenous | “single intravenous (IV) and oral (PO) ascending dose of NRX-1074” NCT01856556 ↗ |
| Route | Oral | “single intravenous (IV) and oral (PO) ascending dose of NRX-1074” NCT01856556 ↗ |